Symbicort SMART Satisfaction From Patient Perspective 2009

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: July 24, 2009
Last updated: March 17, 2010
Last verified: March 2010

To characterize the level of asthma control and patient satisfaction amongst diagnosed asthma sufferers who are currently receiving Symbicort Maintenance and Reliever Therapy (SMART) in Malaysia.


Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Symbicort SMART Satisfaction From Patient Perspective 2009

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Score level of Satisfaction in Asthma Treatment Questionnaire (SATQ) [ Time Frame: After 3 months on SMART - once ] [ Designated as safety issue: No ]
  • Score level of Asthma Control Test (ACT) [ Time Frame: After 3 months on SMART - once ] [ Designated as safety issue: No ]

Enrollment: 205
Study Start Date: August 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 59 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Primary care clinic


Inclusion Criteria:

  • Have been prescribed Symbicort SMART (1 or 2 inhalation twice daily) by their Dr's for the past 3 months
  • Informed consent

Exclusion Criteria:

  • Symbicort SMART treatment < 3 months
  • Patients requiring short courses of oral steroids more than twice in a month
  Contacts and Locations
Please refer to this study by its identifier: NCT00946452

Research Site
Petaling Jaya, Selangor, Malaysia
Sponsors and Collaborators
Principal Investigator: Liam Chong Kin, Professor UMMC
  More Information

No publications provided

Responsible Party: MC MD, AstraZeneca Pharmaceuticals Identifier: NCT00946452     History of Changes
Other Study ID Numbers: NIS-RMY-SYM-2009/1
Study First Received: July 24, 2009
Last Updated: March 17, 2010
Health Authority: Malaysia: Ministry of Health

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Pharmacologic Actions processed this record on April 20, 2014